Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anthoxanthum odoratum pollen is an allergen extract from the pollen of the Sweet Vernal grass. It is not marketed as a standalone drug but is a key active ingredient in allergen immunotherapy (AIT) products designed to treat grass pollen allergies. Notably, it is one of five grass pollen extracts included in ORALAIR, an FDA-approved sublingual tablet for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis. The mechanism of action is based on allergen immunotherapy, which involves administering the allergen to desensitize the immune system, thereby reducing the allergic response and the production of pollen-specific IgE antibodies. This treatment aims to induce long-term tolerance to grass pollen. [20, 21, 22, 26, 31]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anthoxanthum odoratum pollen.